Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Drug Profile

Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Alternative Names: Ipragliflozin L-proline/sitagliptin phosphate - Astellas Pharma/MSD KK; Sitagliptin phosphate/ipragliflozin L-proline - Astellas Pharma/MSD KK; Sitagliptin/ipragliflozin - Astellas Pharma/MSD KK

Latest Information Update: 20 Apr 2015

Price : $50

At a glance

  • Originator Astellas Pharma; MSD KK
  • Class Glucosides; Pyrazines; Small molecules; Thiophenes; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Type 2 diabetes mellitus

Most Recent Events

  • 15 Apr 2015 Early research in Type-2 diabetes mellitus in Japan (PO)
  • 15 Apr 2015 Astellas Pharma and MSD KK agree to co-promote and co-develop ipragliflozin/sitagliptin in Japan for Type 2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top